ARQIS Advises Founders on the Sale of INS to LANXESS

ARQIS advises founders on the sale of INS to LANXESS

ARQIS has advised the founders of the biotech start-up IMD Natural Solutions (INS) on their exit. Specialty chemicals group LANXESS has acquired the Dortmund-based company in order to expand its expertise in biotechnology. Financial details of the transaction were not disclosed.

IMD Natural Solutions develops novel active ingredients from sustainable natural resources for the food, beverage and consumer goods industries. The focus is on the research and development of natural substances with antimicrobial effects.

For LANXESS the acquisition is an important step towards becoming fit for the future in the growing market for natural active ingredients. LANXESS is a leading specialty chemicals company with sales of EUR 9.7 billion in 2017 and about 19,200 employees in 25 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. Through ARLANXEO, the joint venture with Saudi Aramco, LANXESS is also a leading supplier of synthetic rubber.

ARQIS has advised INS for the first time. The contact came about through ARQIS partner Dr. Mirjam Boche.

Advisors to IMD Natural Solutions
ARQIS Rechtsanw’lte (D’sseldorf): Dr. Mirjam Boche (Lead; Corporate/M&A), Marcus Nothhelfer (IP; Munich); Associates: Franziska Korn (Corporate/M&A), Dr. Philipp Maier (IP; Munich)